Scholarlink

<p>Pediatric Central Nervous System (CNS) tumors are the leading cause of cancer-related death in children, yet effective treatment options remain limited. The tumor-associated antigen GD2 is a promising target for immunotherapeutic approaches aimed at treating pediatric CNS cancers; however, its heterogeneous expression within and between tumors can complicate the development of effective strategies. Here we review different aspects of GD2 biology, including its structure, synthesis pathway, and cellular and tissue expression, focusing on pediatric CNS tumors. We provide a detailed overview of the investigational and diagnostic methods for evaluating GD2 expression on freshly dissociated tumor samples, tissue sections, or tumor-derived cell lines, and as a circulating marker in liquid biopsy. Furthermore, we provide a comprehensive overview of GD2-based therapeutic strategies, such as monoclonal antibodies, CAR T-cells, aptamers, vaccines, and multimodal approaches, from preclinical studies to recent clinical applications, highlighting both the promise and challenges of targeting GD2 in these cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月21日

查看全文
  • Alba Clara Fernández-Rilo,
  • Emmanuel de Billy,
  • Giada Del Baldo,
  • Biagio De Angelis,
  • Sabrina Rossi,
  • Francesca Del Bufalo,
  • Concetta Quintarelli,
  • Franco Locatelli,
  • Angela Mastronuzzi,
  • Maria Vinci

摘要

Pediatric Central Nervous System (CNS) tumors are the leading cause of cancer-related death in children, yet effective treatment options remain limited. The tumor-associated antigen GD2 is a promising target for immunotherapeutic approaches aimed at treating pediatric CNS cancers; however, its heterogeneous expression within and between tumors can complicate the development of effective strategies. Here we review different aspects of GD2 biology, including its structure, synthesis pathway, and cellular and tissue expression, focusing on pediatric CNS tumors. We provide a detailed overview of the investigational and diagnostic methods for evaluating GD2 expression on freshly dissociated tumor samples, tissue sections, or tumor-derived cell lines, and as a circulating marker in liquid biopsy. Furthermore, we provide a comprehensive overview of GD2-based therapeutic strategies, such as monoclonal antibodies, CAR T-cells, aptamers, vaccines, and multimodal approaches, from preclinical studies to recent clinical applications, highlighting both the promise and challenges of targeting GD2 in these cancers.